Alvotech Ordinary Shares ALVO 深 滬
等待開盤 09-19 09:30:00 美东时间
7.82
-0.110
-1.39%
華盛通- 最 高8.00
- 今 開7.94
- 成交量 30.83万股
- 最 低 7.75
- 昨 收 7.93
- 總市值 24.16亿
- 52周最高 13.70
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 7.35
- 委 比 -30.25%
- 總股本 3.09亿
- 歷史最高 18.00
- 量 比 1.48
- 振 幅 3.15%
- 歷史最低 5.20
- 每 手 1
- 風險率 1.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
Alvotech announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, September 8-10, 2025. Dr. Balaji Prasad, Chief Strategy Officer, will join a fireside chat on September 10 at 10:45 am EDT. The event will be live-streamed and available for replay for 90 days. Alvotech focuses on developing and manufacturing biosimilar medicines, has launched two biosimilars, and collaborates with global partners to e...
09-04 13:15
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
Alvotech and Advanz Pharma announced the European Commission's approval of Mynzepli® (aflibercept), a biosimilar to Eylea®, for treating conditions like wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusions. Approved across all European Economic Area countries, Mynzepli® is available as a pre-filled syringe and vial. The approval follows a confirmatory clinical study demonstrating therapeutic equivalence ...
08-21 08:30
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
Alvotech, a global biotech company, announced the appointment of Patrik Ling as VP of Investor Relations Scandinavia, based in Stockholm. With over 25 years of experience in the life-science industry, Ling joins Alvotech from DNB Carnegie, where he served as a Senior Equity Analyst covering life-science companies. His background spans marketing, sales, and financial roles, including portfolio management and equity analysis. Alvotech’s chairman an...
08-20 10:05
Soho House, GoodRx Holdings, Dayforce And Other Big Stocks Moving Higher On Monday
U.S. stocks were mostly lower, with the Dow Jones index falling around 0.1% on ...
08-19 01:05
Alvotech shares are trading higher after the company reported a year-over-year increase in H1 financial results.
Alvotech shares are trading higher after the company reported a year-over-year ...
08-14 04:29
Alvotech Non-GAAP EPS of $0.49 beats by $0.49
Alvotech press release (NASDAQ:ALVO): 1H Non-GAAP EPS of $0.49 beats by $0.49. Product revenue was $204.7 million for the six months ended June 30, 2025, compared to $65.9 million for the six months e...
08-14 04:21
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
Alvotech's Earnings: A Preview
Alvotech (NASDAQ:ALVO) is preparing to release its quarterly earnings on Wednes...
08-12 23:01
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
Alvotech will release its first-half 2025 financial results after U.S. markets close on August 13, 2025, and hold a conference call on August 14, 2025, at 8:00 am EDT to discuss the results and recent business highlights. The webcast will be available on Alvotech’s investor portal and archived for 90 days. Alvotech, a global biosimilar developer and manufacturer, has two approved biosimilars and nine candidates in its pipeline targeting various t...
08-06 12:00
